B-Cell Navigator

B-Cell Navigator

B-Cell Navigator: The Dual-Engine Evolution in Antibody Discovery

Access the complete immune repertoire. From immunized samples to a qualified hit panel in just 8-10 weeks.

The B-Cell Navigator is a comprehensive single B cell discovery platform that integrates custom immunisation strategies, parallel technologies with binding and functional screening capabilities, rapid IgG expression, comprehensive hit and lead characterisation to deliver a curated panel of high-quality antibody candidates with speed and precision.

Our host-agnostic platform supports the entire target space, providing a high-throughput solution for both standard soluble antigens and complex membrane targets (GPCRs, Ion Channels). By simultaneously interrogating both memory and plasma cell populations, we ensure that no high-potential lead is left behind.

Discuss Your Project 

B-Cell Navigator: The Dual-Engine Evolution in Antibody Discovery

Access the complete immune repertoire. From immunized samples to a qualified hit panel in just 8-10 weeks.

The B-Cell Navigator is a comprehensive single B cell discovery platform that integrates custom immunisation strategies, parallel technologies with binding and functional screening capabilities, rapid IgG expression, comprehensive hit and lead characterisation to deliver a curated panel of high-quality antibody candidates with speed and precision.

Our host-agnostic platform supports the entire target space, providing a high-throughput solution for both standard soluble antigens and complex membrane targets (GPCRs, Ion Channels). By simultaneously interrogating both memory and plasma cell populations, we ensure that no high-potential lead is left behind.

Discuss Your Project 

B-Cell Navigator: The Dual-Engine Evolution in Antibody Discovery

Access the complete immune repertoire. From immunized samples to a qualified hit panel in just 8-10 weeks.

The B-Cell Navigator is a comprehensive single B cell discovery platform that integrates custom immunisation strategies, parallel technologies with binding and functional screening capabilities, rapid IgG expression, comprehensive hit and lead characterisation to deliver a curated panel of high-quality antibody candidates with speed and precision.

Our host-agnostic platform supports the entire target space, providing a high-throughput solution for both standard soluble antigens and complex membrane targets (GPCRs, Ion Channels). By simultaneously interrogating both memory and plasma cell populations, we ensure that no high-potential lead is left behind.

Discuss Your Project 

The Challenge: Bridging the “Biology Hurdle” and the “Function Gap”

Traditional single B-Cell platforms often force a choice between cell populations, creating a "Biology Hurdle" that misses critical diversity. The B-Cell Navigator closes this gap by mining both the memory B-Cell / Plasmablast compartment and the plasma cell population in parallel.

The Diversity Imperative

Screen millions of B cells to identify rare, high-affinity clones with unique epitopes.

Early Confidence

Generate functional data early to de-risk development and predict downstream success.

Accelerated Entry

Resolve the “Timeline Bottleneck” with a streamlined 8–10 week discovery cycle from sample receipt to hit qualification.

B-Cell Navigator in the FairJourney Bio Value Chain

B-Cell Navigator sits at the Hit Discovery and Lead Selection stages, delivering natively paired, functionally qualified antibody candidates that are ready for lead optimisation, characterisation, and downstream development.

Explore discovery-to-IND

Explore discovery-to-IND

Dual Engine. One Platform. 


The Entire Immune Response

The Platform

B-Cell Navigator is built around a fundamental insight: Memory B-Cells and Plasma cells each require a different optimised screening approach to reveal their best candidates. Rather than choosing one, FairJourney Bio runs both, in parallel, in a single integrated workflow, to deliver a more complete, more diverse, and more functionally qualified hit panel than any single-engine approach can provide.

Discuss with our team

Dual Engine. One Platform. 


The Entire Immune Response

The Platform

B-Cell Navigator is built around a fundamental insight: Memory B-Cells and Plasma cells each require a different optimised screening approach to reveal their best candidates. Rather than choosing one, FairJourney Bio runs both, in parallel, in a single integrated workflow, to deliver a more complete, more diverse, and more functionally qualified hit panel than any single-engine approach can provide.

Discuss with our team

Dual Engine. One Platform. 


The Entire Immune Response

The Platform

B-Cell Navigator is built around a fundamental insight: Memory B-Cells and Plasma cells each require a different optimised screening approach to reveal their best candidates. Rather than choosing one, FairJourney Bio runs both, in parallel, in a single integrated workflow, to deliver a more complete, more diverse, and more functionally qualified hit panel than any single-engine approach can provide.

Discuss with our team

Common Downstream Workflow

Both engines feed into a shared downstream pipeline, ensuring that hits from Memory B-Cells and Plasma cells are processed, characterised, and delivered through the same rigorous workflow.

  • V-gene recovery and cloning

  • Rapid high-throughput IgG expression

  • Supernatant screening

  • Hit panel characterisation

  • Lead panel characterisation and optimisation

Why Dual-Engine Changes the Outcome

  • Explore breadth and diversity: no B-Cell population is left behind.

  • Confirm functional relevance: function is screened at discovery, not downstream

  • Enable confident early decision-making: richer, more qualified hit panels

  • Capture diversity others miss: scale and biology working together

  • Reduce attrition downstream: hits are functionally pre-validated before lead selection begins

Timeline

Qualified hit panel delivered in 8–10 weeks post immunisation.

Discuss with our team

Timeline

Qualified hit panel delivered in 8–10 weeks post immunisation.

Discuss with our team

Timeline

Qualified hit panel delivered in 8–10 weeks post immunisation.

Discuss with our team

What You Receive

  • Sequence-confirmed antibody hits with 

natively paired VH-VL sequences

  • Binding confirmation data: antigen specificity, 

hit frequency, clone diversity

  • Functional screening data where applicable: 

blocking, agonism, antagonism, internalisation

  • Paired V-gene sequences for all confirmed hits

  • Visual confirmation of monoclonality for sorted cells

  • Hit panel characterisation data

  • Full data security — your programme data is never 

shared across projects

Seamless Integration

B-Cell Navigator hits move directly into FairJourney Bio's lead optimisation and development capability with no data loss and no handoff risk

  • DeepDesign Engineering — affinity maturation, humanisation, lead optimisation

  • FullSpectrum Characterization — biophysical and biochemical profiling

  • AtomicLevel Cryo-EM — structural analysis and epitope mapping

  • AnyFormat Manufacturing — cell line development and GMP manufacturing

  • FastTrack IND — regulatory support and IND filing

The B-Cell Navigator Workflow: Parallel Discovery & Integrated Precision

The B-Cell Navigator Workflow: Parallel Discovery & Integrated Precision

The B-Cell Navigator Workflow: Parallel Discovery & Integrated Precision

Phase I. Repertoire Development and Sample Versatility

We maximize the probability of success by starting with a robust and diverse immune repertoire.

- Agnostic Sourcing: We can work with Wild-Type mice, variety of transgenic mice expressing human antibody repertoire, and human samples (e.g., convalescent PBMCs).

- Tailored Immunization: Custom protocols integrated with deep expertise working with a variety of immunogens (proteins, target-expressing cells, VLPs, mRNA-LNP, DNA) and strategies to overcome immunological tolerance.

- Rigorous QC: Thorough quality control of immune samples and strategic scale-up of the repertoire to ensure optimal cell viability and frequency of target-specific cells.

Phase I. Repertoire Development and Sample Versatility

We maximize the probability of success by starting with a robust and diverse immune repertoire.

- Agnostic Sourcing: We can work with Wild-Type mice, variety of transgenic mice expressing human antibody repertoire, and human samples (e.g., convalescent PBMCs).

- Tailored Immunization: Custom protocols integrated with deep expertise working with a variety of immunogens (proteins, target-expressing cells, VLPs, mRNA-LNP, DNA) and strategies to overcome immunological tolerance.

- Rigorous QC: Thorough quality control of immune samples and strategic scale-up of the repertoire to ensure optimal cell viability and frequency of target-specific cells.

Phase I. Repertoire Development and Sample Versatility

We maximize the probability of success by starting with a robust and diverse immune repertoire.

- Agnostic Sourcing: We can work with Wild-Type mice, variety of transgenic mice expressing human antibody repertoire, and human samples (e.g., convalescent PBMCs).

- Tailored Immunization: Custom protocols integrated with deep expertise working with a variety of immunogens (proteins, target-expressing cells, VLPs, mRNA-LNP, DNA) and strategies to overcome immunological tolerance.

- Rigorous QC: Thorough quality control of immune samples and strategic scale-up of the repertoire to ensure optimal cell viability and frequency of target-specific cells.

Phase II. Dual-Engine Parallel Screening

We increase the probability of finding rare and diverse hits by using Dual Screening Power to interrogate disparate B-Cell populations simultaneously.

- Engine A (Imaging Spectral Sorting): Utilizing the BD FACSDiscover™ S8, we integrate real-time imaging with high-parameter spectral flow cytometry. This allows us to exclude artifacts and sort rare target-specific memory B cells with unprecedented precision.

- Engine B (Microfluidic Picodroplet Functional Screen): Utilizing the Cyto-Mine® Chroma, we screen millions of plasma cells per day within individual picolitre-sized reaction vessels. This enables multiplexed functional assays (binding to conformational epitopes, ligand blocking, agonism, antagonism, internalization, neutralization ligand blocking, neutralization, and secretion) early at the single-cell level.

Phase II. Dual-Engine Parallel Screening

We increase the probability of finding rare and diverse hits by using Dual Screening Power to interrogate disparate B-Cell populations simultaneously.

- Engine A (Imaging Spectral Sorting): Utilizing the BD FACSDiscover™ S8, we integrate real-time imaging with high-parameter spectral flow cytometry. This allows us to exclude artifacts and sort rare target-specific memory B cells with unprecedented precision.

- Engine B (Microfluidic Picodroplet Functional Screen): Utilizing the Cyto-Mine® Chroma, we screen millions of plasma cells per day within individual picolitre-sized reaction vessels. This enables multiplexed functional assays (binding to conformational epitopes, ligand blocking, agonism, antagonism, internalization, neutralization ligand blocking, neutralization, and secretion) early at the single-cell level.

Phase II. Dual-Engine Parallel Screening

We increase the probability of finding rare and diverse hits by using Dual Screening Power to interrogate disparate B-Cell populations simultaneously.

- Engine A (Imaging Spectral Sorting): Utilizing the BD FACSDiscover™ S8, we integrate real-time imaging with high-parameter spectral flow cytometry. This allows us to exclude artifacts and sort rare target-specific memory B cells with unprecedented precision.

- Engine B (Microfluidic Picodroplet Functional Screen): Utilizing the Cyto-Mine® Chroma, we screen millions of plasma cells per day within individual picolitre-sized reaction vessels. This enables multiplexed functional assays (binding to conformational epitopes, ligand blocking, agonism, antagonism, internalization, neutralization ligand blocking, neutralization, and secretion) early at the single-cell level.

Phase III. V-gene Recovery, Rapid IgG Expression and Hit Qualification

Once the highest-potential cells are identified, we capture the natural immune signatures.

- Native Pairing: High-fidelity recovery of naturally paired VH and VL sequences to preserve in vivo affinity maturation.

- Rapid Expression: Our proprietary high-throughput platform moves from single B cell hits to characterized IgG supernatants in less than 3 weeks.

- Sequence-Led Qualification: Every candidate hit undergoes initial binding assessment, off-rate (koff) analysis, and sequence liability checks (PTMs, deamidation, oxidation) to generate a qualified hit panel and de-risked lead panel.

Phase III. V-gene Recovery, Rapid IgG Expression and Hit Qualification

Once the highest-potential cells are identified, we capture the natural immune signatures.

- Native Pairing: High-fidelity recovery of naturally paired VH and VL sequences to preserve in vivo affinity maturation.

- Rapid Expression: Our proprietary high-throughput platform moves from single B cell hits to characterized IgG supernatants in less than 3 weeks.

- Sequence-Led Qualification: Every candidate hit undergoes initial binding assessment, off-rate (koff) analysis, and sequence liability checks (PTMs, deamidation, oxidation) to generate a qualified hit panel and de-risked lead panel.

Phase III. V-gene Recovery, Rapid IgG Expression and Hit Qualification

Once the highest-potential cells are identified, we capture the natural immune signatures.

- Native Pairing: High-fidelity recovery of naturally paired VH and VL sequences to preserve in vivo affinity maturation.

- Rapid Expression: Our proprietary high-throughput platform moves from single B cell hits to characterized IgG supernatants in less than 3 weeks.

- Sequence-Led Qualification: Every candidate hit undergoes initial binding assessment, off-rate (koff) analysis, and sequence liability checks (PTMs, deamidation, oxidation) to generate a qualified hit panel and de-risked lead panel.

Phase IV. Cross-Platform Integration

The B-Cell Navigator is one of the gateways to FJBio’s integrated solution packages, connecting discovery to clinical readiness due to the adjunct Mammalian Display, a CMC reporter technology.

- Advanced Production: Scale-up and purification of stable, high-titer antibody candidates.

- Holistic Characterization: Advanced biophysical profiling (SPR, Epitope Binning, DSC, SEC-MALS), structural biology (Cryo-EM), and early-stage and late-stage developability assessments to support your IND filing.

- Lead Optimization: Engineering lead candidates (e.g., affinity maturation) to fine-tune the final therapeutic profile.

Phase IV. Cross-Platform Integration

The B-Cell Navigator is one of the gateways to FJBio’s integrated solution packages, connecting discovery to clinical readiness due to the adjunct Mammalian Display, a CMC reporter technology.

- Advanced Production: Scale-up and purification of stable, high-titer antibody candidates.

- Holistic Characterization: Advanced biophysical profiling (SPR, Epitope Binning, DSC, SEC-MALS), structural biology (Cryo-EM), and early-stage and late-stage developability assessments to support your IND filing.

- Lead Optimization: Engineering lead candidates (e.g., affinity maturation) to fine-tune the final therapeutic profile.

Phase IV. Cross-Platform Integration

The B-Cell Navigator is one of the gateways to FJBio’s integrated solution packages, connecting discovery to clinical readiness due to the adjunct Mammalian Display, a CMC reporter technology.

- Advanced Production: Scale-up and purification of stable, high-titer antibody candidates.

- Holistic Characterization: Advanced biophysical profiling (SPR, Epitope Binning, DSC, SEC-MALS), structural biology (Cryo-EM), and early-stage and late-stage developability assessments to support your IND filing.

- Lead Optimization: Engineering lead candidates (e.g., affinity maturation) to fine-tune the final therapeutic profile.

Fullspectrum Characterization

fullspectrum-characterization

0

AnyFormat Manufacturing

anyformat-manufacturing

0

DeepDesign Engineering

deepdesign-engineering

0

FunctionInsight Assays

functioninsight-assays

0

B-Cell Navigator

b-cell-navigator

0

Solutions

solutions

1

Platforms & Technologies

platforms-technologies

0

Why FJBio

why-fjbio

0

Events & Resources

events-resources

0

Company

company

0

About

about

0

Antibody Discovery

antibody-discovery

0

Protein Production

protein-production

0

AtomicLevel Cryo-EM

atomic-level-cryo-em

0

FastTrack IND

fasttrack-ind

0

Biologistics

biologistics

0

Leadership

leadership

0

Careers

careers

0

News & Insights

news-insights

0

Case Studies

case-studies

0

Fact Sheets

fact-sheets

0

CellCraft Solutions

cellcraft-solutions

0

Cryo-EM

cryo-em

0

Display Platforms

display-platforms

0

Events

events

0

Library Diversity

library-diversity

0

MultiPath Discovery

multipath-discovery

0

Publications & Posters

publications-posters

0

Resources

resources

0

Screening | Analytics | Data Engines

screening-analytics-data-engines

0

Single B-Cell Screening

single-b-cell-screening

0

The Antibody Series Conference

the-antibody-series-conference

0

Tumbler™

tumbler

0

Webinars

webinars

0

White papers

whitepapers

0

Contact Us

contact-us

0